Autopsy report · NCT02392676

Olaparib Maintenance Treatment Versus Placebo in Patients With PSR Ovarian Cancer Who Are in CR or PR to Platinum-based Chemotherapy and Whose Tumours Carry sBRCAm or HRR-associated Genes Mutations

Cause of deathOther Automatic label, confidence 0.3, unverified. How labels are made.

“Study is unlikely to be feasible given the evolving ovarian cancer landscape and alternative studies have the potential to meet future clinical demand.”

The sponsor’s own words in the registry.

Life of this trial

Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status: Withdrawn
Phase: Phase 3
Sponsor: AstraZeneca
Sponsor type: Industry
Conditions: Platinum Sensitive Relapsed Ovarian Cancer
Interventions: OLAPARIB; PLACEBO
Participants: 0
Sites: 29
Countries: Peru, Philippines, South Korea, United Kingdom, United States

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.